Stock RVV REVIVE THERAPEUTICS LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Revive Therapeutics Ltd.

Equities

RVV

CA7615161030

Market Closed - Canadian Securities Exchange
Other stock markets
 12:32:24 2024-06-24 EDT 		5-day change 1st Jan Change
0.015 CAD 0.00% Intraday chart for Revive Therapeutics Ltd. -25.00% -50.00%
06-12 Revive Therapeutics Ltd. Provides Update on FDA Type C Meeting for Clinical Study of Bucillamine to Treat Long Covid CI
06-10 Revive Therapeutics Ltd. Provides Update from FDA Meeting for Long Covid Diagnostic Product CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Revive Therapeutics Provides Update on FDA Type C Meeting for Clinical Study of Bucillamine to Treat Long COVID
GL
Revive Therapeutics Provides Update From FDA Meeting for Long COVID Diagnostic Product
GL
Revive Therapeutics : Document
PU
Revive Therapeutics : Document
PU
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
GL
Revive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product
GL
Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder
GL
Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder
AQ
Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID
GL
Revive Therapeutics : Document
PU
Revive Therapeutics : Document
PU
Revive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID
GL
Revive Therapeutics Provides Corporate Update
GL
Revive Therapeutics Provides Corporate Update
AQ
Revive Therapeutics : Document
PU
Revive Therapeutics : Document
PU
Revive Therapeutics : Document
PU
Revive Therapeutics Ltd. Announces Closing of the Second and Final Tranche of Its Private Placement for Gross Proceeds of $1,187,110
GL
Revive Therapeutics Explores the Use of Bucillamine for Long COVID
GL
Revive Therapeutics Explores the Use of Bucillamine for Long COVID
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RVV Stock
  4. News Revive Therapeutics Ltd.
  5. Press Releases